PLBD2

Across TCGA cell cohorts, PLBD2 mutation is significantly associated with the drug of many other genes, with 24 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible PLBD2-associated genes across cancer lineages are Lestaurtinib, Nutlin-3a (-), and Paclitaxel. Each is linked with PLBD2 in more than 1 cancer types. Because this analysis shows association rather than direction, both PLBD2-to-partner and partner-to-PLBD2 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Lestaurtinib grouped by PLBD2-low versus PLBD2-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (PLBD2→partner) and Y-score (partner→PLBD2) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Lestaurtinib →	+0.614	+2.710	.012	.043	3	1
LARGE_INTESTINE	Nutlin-3a (-) →	+0.778	+2.646	.034	.047	3	1
LARGE_INTESTINE	Paclitaxel →	+0.717	+2.649	.032	.046	3	1
LARGE_INTESTINE	GSK1904529A →	+0.551	+2.700	<.001	.030	3	1
LARGE_INTESTINE	PRIMA-1MET →	+0.702	+2.646	.007	.047	3	1
LARGE_INTESTINE	Entospletinib →	+0.655	+2.646	<.001	.047	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 24 associations by consensus.

Lestaurtinib by PLBD2 expression — LARGE_INTESTINE

Explore this box plot interactively →